Pregene lands up to $1.52B deal with Kite for in vivo therapies

Chinese biotech Pregene Biopharma has entered into a licensing pact with Gilead's Kite Pharma that could be worth as much as $1.52 billion, under a deal that looks to accelerate the development of next-generation ...